Neurology

PACE
In this month’s “Virtual Lecture” Eoin Flanagan, M.D., B.Ch., reviews how to diagnose autoimmune encephalitis, what to watch that may suggest a different diagnosis, discuss neural autoantibodies interpretation and putting test results into clinical context.

By MCL Education • January 18, 2023

Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.

By Barbara J. Toman • January 17, 2023

As part of Mayo Clinic’s Neuro-Oncology practice, the Division of Laboratory Genetics and Genomics tests about 50 brain tumors a week, and upwards of 1,500 brain tumors a year from all over the world.

By Chris Bahnsen • January 2, 2023

Ed Garber spent months in physical and neurological decline while a cohort of care providers and specialists searched for the root cause of his symptoms. That search for answers ended after testing by Mayo Clinic Laboratories gave them the confirmatory diagnosis they needed.

By Cory Pedersen • December 5, 2022

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.

By Barbara J. Toman • August 23, 2022

Mayo Clinic Laboratories offers an innovative testing solution for the early detection of Alzheimer's disease. Learn more at the AAIC 2022 tradeshow.

By Meghann Southwick • July 27, 2022

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

By Barbara J. Toman • July 26, 2022

Mayo Clinic neuropathologist Caterina Giannini, M.D., Ph.D., received the American Association of Neuropathologists’ (AANP) award for Meritorious Contributions to Neuropathology during the AANP’s 98th annual meeting in June.

By Cory Pedersen • July 18, 2022

As a two-time brain tumor survivor, Alex Kraatz has been through more harrowing medical experiences in his 34 years than most people face in a lifetime. But Alex’s fighting spirit, coupled with precision laboratory testing and cutting-edge treatments, have propelled him forward, keeping him hopeful despite the odds.

By Robin Huiras-Carlson • July 11, 2022

This July, Mayo Clinic’s Neuroimmunology Laboratory will showcase its revolutionary approach to autoimmune neurology testing at the American Academy of Neurology (AAN) Summer Conference: Autoimmune Neurology and Neurology Year in Review in San Francisco. During the meeting, Mayo Clinic Laboratories representatives will highlight our growing list of disease-specific tests and discuss how results can inform decision-making and improve treatment outcomes.

By Robin Huiras-Carlson • June 16, 2022

PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” John Mills, Ph.D., provides information related to work that has been done in Mayo Clinic’s neuroimmunology laboratory which has played a central role in driving the field of autoimmune neurology. Over time it has driven an increase in testing volume, a number of different testing platforms, testing complexity, and a constant influx of novel laboratory-developed tests.

By MCL Education • May 25, 2022

Join Mayo Clinic’s autoimmune neurology testing leaders for a live Zoom Q&A discussion as they discuss the rationale behind and benefits of Mayo Clinic Laboratories’ streamlined, phenotype-specific approach to testing for autoimmune neurological disorders.

By Robin Huiras-Carlson • May 17, 2022

Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.

By Barbara J. Toman • May 17, 2022